July 24, 2026

FDA Approves Ophthalmic Bevacizumab

The approval establishes the first and only FDA-approved ophthalmic formulation of bevacizumab for neovascular age-related macular degeneration in the US.

Conexiant

July 15, 2026

Could Gene Therapy Change Retina Care for Rural Veterans?

Drawing on his experience caring for veterans in northern California, Frank Brodie, MD, MBA, explains why gene therapy may be particularly meaningful for patients who travel long distances for routine anti-VEGF treatment.

Retinal Physician

July 01, 2026

Medical Oddities: Do Jellyfish Hold a Healing Secret?

Jellyfish, pets, watermelon, brain implants, and fennel fuel this week's surprises.

Conexiant

May 05, 2026

Lutein Supplementation May Improve Outcomes in Early AMD

Meta-analysis found statistically significant improvements, with clearest benefits in early-stage disease

Conexiant

May 01, 2026

Racing Toward Efficient AI Workflows

At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.

Retinal Physician

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 28, 2026

Inside the Aging Eye

A comprehensive new Elsevier publication brings global expertise together to unpack how aging drives ocular structure, function, and disease

The Ophthalmologist

April 20, 2026

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

Conexiant

March 24, 2026

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Conexiant

March 24, 2026

Artificial Tears Reduce Dryness Symptoms in 1-Month Study

Prospective multicenter study without a control group shows symptom scores reduced by more than half after 4 weeks of treatment

Conexiant